Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Neoplasms 27Colorectal Neoplasms 26Neoplasm Metastasis 24Recurrence 22Ovarian Neoplasms 22Pancreatic Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Prostatic Neoplasms 18Melanoma 17Glioblastoma 15Lymphoma, Large B-Cell, Diffuse 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 13Endometrial Neoplasms 13Multiple Myeloma 12Lung Neoplasms 12Colonic Neoplasms 12Triple Negative Breast Neoplasms 11Carcinoma, Renal Cell 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Glioma 10Gastrointestinal Neoplasms 10Rectal Neoplasms 9Lymphoma, Follicular 9Lymphoma 9Head and Neck Neoplasms 8Burkitt Lymphoma 8

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Immune System Diseases × 30 days × Clear all
NCT05826535 2026-05-28

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Phase 1/2 Recruiting
270 enrolled
Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡